Related Experiment Video

Updated: Aug 24, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

Yoshifumi Takei1, Kenji Kadomatsu, Yukio Yuzawa

  • 1Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Japan. takei@med.nagoya-u.ac.jp

Cancer Research
|May 20, 2004
PubMed

Insights

This study introduces a novel RNA interference system to block vascular endothelial growth factor (VEGF) in prostate cancer. The developed VEGF small interfering RNA (siRNA) effectively inhibited tumor growth and angiogenesis in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Vascular endothelial growth factor (VEGF) is crucial for angiogenesis in development and diseases like cancer.
  • Pathological angiogenesis contributes to tumor growth and metastasis.

Purpose of the Study:

  • To develop and evaluate a novel RNA interference (RNAi) system for blocking VEGF.
  • To assess the efficacy of VEGF-targeting small interfering RNA (siRNA) in a prostate cancer model.

Main Methods:

  • Developed siRNA targeting human VEGF.
  • Tested siRNA efficacy in PC-3 prostate cancer cells in vitro.
  • Evaluated VEGF siRNA with atelocollagen in a PC-3 subcutaneous xenograft mouse model.

Main Results:

  • VEGF siRNA significantly inhibited VEGF secretion in PC-3 cells.
  • The combination of VEGF siRNA and atelocollagen suppressed tumor angiogenesis and growth.
  • Atelocollagen facilitated siRNA stabilization and efficient transfection in tumors.

Conclusions:

  • RNA interference targeting VEGF is a promising strategy for prostate cancer therapy.
  • Atelocollagen serves as an effective delivery vehicle for VEGF siRNA, enhancing therapeutic outcomes.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

DNA Vector-based RNA Interference to Study Gene Function in Cancer13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...